Online inquiry

IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5676MR)

This product GTTS-WQ5676MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GPNMB gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005340.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10457
UniProt ID Q14956
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5676MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14778MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ768MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ9849MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ852MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ11202MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ4020MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ6383MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ10277MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFG 316
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW